Common Warts Market Snapshot (2023 to 2033)

The global common warts market garnered a market value of US $ 770 Million in 2023 and is expected to accumulate a market value of US$ 1100 Million by registering a CAGR of 3.6% in the forecast period 2023 to 2033. The worldwide common warts market was extremely strong in 2021 and is predicted to exhibit a quick revenue CAGR during the forecast period. Immunosuppression is a substantial risk factor for persistent infections with Human Papilloma Viruses (HPV) and HPV-associated illness, with a frequency of 10% to 20% among school-aged children.

During the COVID pandemic, the number of immunocompromised people grew, leading to market expansion. However, the worldwide common warts market might be limited by high treatment prices and a lack of treatment availability. During the projected period, factors such as the expanding geriatric population are likely to fuel market revenue growth. The growing number of people being diagnosed with warts, owing to developments in diagnostics and HPV infections, is a key driver driving market expansion.

According to the Centers for Disease Control and Prevention, 340,000 to 360,000 people are affected by HPV-related genital warts each year. In the USA, approximately one in every 100 sexually active persons has genital warts at any one time. Moreover, the increasing frequency of warts in the general population is expected to increase the market for common warts. Furthermore, the market is expanding as a result of a rise in scientific trials conducted by various pharmaceutical companies and an increased need for specific therapy to address various issues caused by common warts. These are the variables that are driving the common warts market forward.

Data Points Key Statistics
Expected Market Value (2023) US$ 770 Million
Anticipated Forecast Value (2033) US$ 1,100 Million
Projected Growth Rate (2023 to 2033) 3.6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Common Warts Demand Analysis (2017 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for common warts is projected to increase at a CAGR of 3.6% during the forecast period between 2022 and 2032, reaching a total of US$ 1,100 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 2%.

The recurrence rate of genital warts treated with topical podophyllotoxin therapy ranges between 6% and 100%. According to the Centers for Disease Control and Prevention (CDC), anogenital warts often reoccur within three months. Thus, when the recurrence incidence of warts increases, so does the use of goods and therapy, driving the market for common warts.

HPV viruses promote excessive and fast development of keratin, a hard protein found on the skin's top layer. According to the Anal Cancer Foundation, an estimated 14 million people in the USA are infected with HPV each year. According to the Centers for Disease Control and Prevention (CDC), genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the USA each year. As a result, an increase in the prevalence of warts and HPV infections supports the expansion of the common warts market.

Which are Some Prominent Drivers of Common Warts Market?

The Increasing Prevalence of Common Warts and HPV infections is propelling Market Growth

People with weaker immune systems as a result of organ transplants, major illnesses such as cancer or AIDS, and atopic disorders are more likely to get warts. As a result, an increase in the number of cancer patients raises the prevalence of warts, driving the common warts market.

An increase in the number of HPV infections increases the danger of warts and, as a result, the market. According to the Anal Cancer Foundation, an estimated 14 million people in the USA are infected with HPV each year. According to the Centers for Disease Control and Prevention, genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the USA each year, and they normally appear 2 to 3 months after HPV infection.

There are several treatments available for warts, but recurrences are common. A large majority of instances of genital warts do not respond to therapy and frequently reoccur, especially when infections from HPV have a protracted incubation period. As a result, an increase in the recurrence rate of common warts increases the need for products and therapy. This, in turn, is projected to fuel the market for common warts.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which are the Trough Areas faced by the Common Warts Market?

The Common Warts Market is being Hampered by a Low Diagnostic Rate due to a Lack of Awareness

The expansion of the worldwide common warts market is anticipated to be impeded by a lack of knowledge of the diagnosis, which results in fewer reported instances and, as a result, less relevance for treatment choices. Although the frequency of warts is increased, the diagnostic rate in patients is low.

For example, according to the 2018 Health Protection Report, the prevalence of genital warts diagnosis among girls aged 15 to 17 in England accessing sexual health services reduced by 92% compared to 2014.

Region-Wise Insights

How will Common Warts Market Demand progress in the Asia Pacific?

Government Support to Raise Awareness about Sexually Transmitted Diseases Widening Profit Margins

Over the projection period, Asia Pacific is predicted to have high revenue CAGR. There is a significant growth in the elderly population in nations such as China, India, and others.

The region's development rate will be enhanced due to the presence of generic producers and the expansion of healthcare facilities. These important drivers are projected to fuel market revenue growth throughout the forecast period.

Government support to raise awareness about sexually transmitted diseases, an increase in demand for advanced therapeutics, an increase in the prevalence of HPV infections, a rising economy, and a shift in sexual lifestyles in the area are key drivers of the Asia Pacific common warts market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Common Warts in North America?

Increase in Pharmaceutical Firms' Research and Development Efforts to Accelerate Market Growth

The development of the North American market is attributable to an increase in pharmaceutical firms' Research and Development efforts, a high rate of treatment acceptance in healthcare facilities, and a rise in knowledge about the impacts of common warts. North America is expected to grow at a CAGR of 3.5% in the assessment period 2023 to 2033.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which Drug Type is expected to Remain Highly Sought After?

Because of Its Low Cost, Salicylic Acid Improves Clinical Outcomes

There is a growing desire for common warts therapy that leaves no scars and gives lifetime protection against HPV. As a result, businesses in the common warts market are focusing more on tissue keratolysis in order to improve patient results.

Tissue keratolysis, which uses salicylic acid, is popular in over-the-counter (OTC) drugs. This is clear since salicylic acid, a chemical destruction therapy option, is predicted to increase at an exponential rate in the common warts market throughout the projection period.

Market Competition

Key players in the common warts market are Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassiopeia Pharmaceuticals, Innovax, and Torii Pharmaceutical Co. Ltd.

Recent Developments

  • In April 2020, Orgenesis Inc. acquired Tamir Biotechnology, Inc., including Ranpirnase, Tamir Bio's broad-spectrum antiviral platform. Total stock and cash consideration were about USD 21 million based on stock valuation at the time of close.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 770 Million
Market Value in 2033 US$ 1,100 Million
Growth Rate CAGR of 3.6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Diagnosis Procedure
  • Drug Type
  • Medication Class
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Nielsen BioSciences
  • Verrica Pharmaceutical
  • Aclaris Therapeutics, Inc.
  • KinoPharma, Inc.
  • pHion Therapeutics
  • Orgenesis
  • Novan
  • Cassopeia Pharmaceuticals
  • Innovax
Customization Available Upon Request

Key Segments Profiled in the Common Warts Market Industry Survey

Common Warts Market by Diagnosis:

  • Biopsy
  • Excision

Common Warts Market by Drug Type:

  • Imiquimod
  • Silver Nitrate
  • Glutaraldehyde
  • Salicylic Acid
  • Formaldehyde
  • Aminolevulinic Acid

Common Warts Market by Medication Class:

  • Topical Retinoids
  • Oral Retinoids

Common Warts Market by Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the anticipated growth of the common warts market until 2033?

FMI projects the global common warts market to expand at a 3.6% value CAGR by 2033

What is the estimated market value of common warts in 2023?

The global common warts market is estimated at a market value of US$ 770 Million

What is the estimated market value of common warts market expected in 2033?

The global market for common warts treatment is expected to garner a market value of US$ 1100 Million

Which region is forecast to be the most lucrative for Common Warts market growth?

As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023 to 2033.

Which are some prominent common warts treatment providers?

Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassopeia Pharmaceuticals, Innovax and Torii Pharmaceutical Co. Ltd., are some prominent Common Warts manufacturers

What is the expected market share of North America in the common warts domain?

North America is expected to grow at a CAGR of 3.5% in the assessment period 2023 to 2033.

What is the expected market share of Europe for Common Warts?

Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023 to 2033.

Which drug type is expected to hold the largest market share for common warts in the forecast period 2023 to 2033?

The Salicylic Acid segment is expected to hold the largest market share for common warts in the forecast period 2023 to 2033.

Table of Content
1. Executive Summary | Common Warts Market
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis Procedure
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis Procedure, 2018 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis Procedure, 2023 to 2033
        5.3.1. Biopsy
        5.3.2. Excision
    5.4. Y-o-Y Growth Trend Analysis By Diagnosis Procedure, 2018 to 2022
    5.5. Absolute $ Opportunity Analysis By Diagnosis Procedure, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
        6.3.1. Imiquimod
        6.3.2. Silver Nitrate
        6.3.3. Glutaraldehyde
        6.3.4. Salicylic Acid
        6.3.5. Formaldehyde
        6.3.6. Aminolevulinic Acid
    6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
    6.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Medication Class
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Medication Class, 2018 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Medication Class, 2023 to 2033
        7.3.1. Topical Retinoids
        7.3.2. Oral Retinoids
    7.4. Y-o-Y Growth Trend Analysis By Medication Class, 2018 to 2022
    7.5. Absolute $ Opportunity Analysis By Medication Class, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Europe
        8.3.4. Asia Pacific
        8.3.5. Middle East and Africa (MEA)
    8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        9.2.1. By Country
            9.2.1.1. United States of America
            9.2.1.2. Canada
        9.2.2. By Diagnosis Procedure
        9.2.3. By Drug Type
        9.2.4. By Medication Class
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Diagnosis Procedure
        9.3.3. By Drug Type
        9.3.4. By Medication Class
    9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Diagnosis Procedure
        10.2.3. By Drug Type
        10.2.4. By Medication Class
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Diagnosis Procedure
        10.3.3. By Drug Type
        10.3.4. By Medication Class
    10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. United Kingdom
            11.2.1.3. France
            11.2.1.4. Spain
            11.2.1.5. Italy
            11.2.1.6. Rest of Europe
        11.2.2. By Diagnosis Procedure
        11.2.3. By Drug Type
        11.2.4. By Medication Class
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Diagnosis Procedure
        11.3.3. By Drug Type
        11.3.4. By Medication Class
    11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. China
            12.2.1.2. Japan
            12.2.1.3. South Korea
            12.2.1.4. Singapore
            12.2.1.5. Thailand
            12.2.1.6. Indonesia
            12.2.1.7. Australia
            12.2.1.8. New Zealand
            12.2.1.9. Rest of Asia Pacific
        12.2.2. By Diagnosis Procedure
        12.2.3. By Drug Type
        12.2.4. By Medication Class
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Diagnosis Procedure
        12.3.3. By Drug Type
        12.3.4. By Medication Class
    12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. GCC Countries
            13.2.1.2. South Africa
            13.2.1.3. Israel
            13.2.1.4. Rest of MEA
        13.2.2. By Diagnosis Procedure
        13.2.3. By Drug Type
        13.2.4. By Medication Class
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Diagnosis Procedure
        13.3.3. By Drug Type
        13.3.4. By Medication Class
    13.4. Key Takeaways
14. Key Countries Market Analysis
    14.1. United States of America
        14.1.1. Pricing Analysis
        14.1.2. Market Share Analysis, 2022
            14.1.2.1. By Diagnosis Procedure
            14.1.2.2. By Drug Type
            14.1.2.3. By Medication Class
    14.2. Canada
        14.2.1. Pricing Analysis
        14.2.2. Market Share Analysis, 2022
            14.2.2.1. By Diagnosis Procedure
            14.2.2.2. By Drug Type
            14.2.2.3. By Medication Class
    14.3. Brazil
        14.3.1. Pricing Analysis
        14.3.2. Market Share Analysis, 2022
            14.3.2.1. By Diagnosis Procedure
            14.3.2.2. By Drug Type
            14.3.2.3. By Medication Class
    14.4. Mexico
        14.4.1. Pricing Analysis
        14.4.2. Market Share Analysis, 2022
            14.4.2.1. By Diagnosis Procedure
            14.4.2.2. By Drug Type
            14.4.2.3. By Medication Class
    14.5. Germany
        14.5.1. Pricing Analysis
        14.5.2. Market Share Analysis, 2022
            14.5.2.1. By Diagnosis Procedure
            14.5.2.2. By Drug Type
            14.5.2.3. By Medication Class
    14.6. United Kingdom
        14.6.1. Pricing Analysis
        14.6.2. Market Share Analysis, 2022
            14.6.2.1. By Diagnosis Procedure
            14.6.2.2. By Drug Type
            14.6.2.3. By Medication Class
    14.7. France
        14.7.1. Pricing Analysis
        14.7.2. Market Share Analysis, 2022
            14.7.2.1. By Diagnosis Procedure
            14.7.2.2. By Drug Type
            14.7.2.3. By Medication Class
    14.8. Spain
        14.8.1. Pricing Analysis
        14.8.2. Market Share Analysis, 2022
            14.8.2.1. By Diagnosis Procedure
            14.8.2.2. By Drug Type
            14.8.2.3. By Medication Class
    14.9. Italy
        14.9.1. Pricing Analysis
        14.9.2. Market Share Analysis, 2022
            14.9.2.1. By Diagnosis Procedure
            14.9.2.2. By Drug Type
            14.9.2.3. By Medication Class
    14.10. China
        14.10.1. Pricing Analysis
        14.10.2. Market Share Analysis, 2022
            14.10.2.1. By Diagnosis Procedure
            14.10.2.2. By Drug Type
            14.10.2.3. By Medication Class
    14.11. Japan
        14.11.1. Pricing Analysis
        14.11.2. Market Share Analysis, 2022
            14.11.2.1. By Diagnosis Procedure
            14.11.2.2. By Drug Type
            14.11.2.3. By Medication Class
    14.12. South Korea
        14.12.1. Pricing Analysis
        14.12.2. Market Share Analysis, 2022
            14.12.2.1. By Diagnosis Procedure
            14.12.2.2. By Drug Type
            14.12.2.3. By Medication Class
    14.13. Singapore
        14.13.1. Pricing Analysis
        14.13.2. Market Share Analysis, 2022
            14.13.2.1. By Diagnosis Procedure
            14.13.2.2. By Drug Type
            14.13.2.3. By Medication Class
    14.14. Thailand
        14.14.1. Pricing Analysis
        14.14.2. Market Share Analysis, 2022
            14.14.2.1. By Diagnosis Procedure
            14.14.2.2. By Drug Type
            14.14.2.3. By Medication Class
    14.15. Indonesia
        14.15.1. Pricing Analysis
        14.15.2. Market Share Analysis, 2022
            14.15.2.1. By Diagnosis Procedure
            14.15.2.2. By Drug Type
            14.15.2.3. By Medication Class
    14.16. Australia
        14.16.1. Pricing Analysis
        14.16.2. Market Share Analysis, 2022
            14.16.2.1. By Diagnosis Procedure
            14.16.2.2. By Drug Type
            14.16.2.3. By Medication Class
    14.17. New Zealand
        14.17.1. Pricing Analysis
        14.17.2. Market Share Analysis, 2022
            14.17.2.1. By Diagnosis Procedure
            14.17.2.2. By Drug Type
            14.17.2.3. By Medication Class
    14.18. GCC Countries
        14.18.1. Pricing Analysis
        14.18.2. Market Share Analysis, 2022
            14.18.2.1. By Diagnosis Procedure
            14.18.2.2. By Drug Type
            14.18.2.3. By Medication Class
    14.19. South Africa
        14.19.1. Pricing Analysis
        14.19.2. Market Share Analysis, 2022
            14.19.2.1. By Diagnosis Procedure
            14.19.2.2. By Drug Type
            14.19.2.3. By Medication Class
    14.20. Israel
        14.20.1. Pricing Analysis
        14.20.2. Market Share Analysis, 2022
            14.20.2.1. By Diagnosis Procedure
            14.20.2.2. By Drug Type
            14.20.2.3. By Medication Class
15. Market Structure Analysis
    15.1. Competition Dashboard
    15.2. Competition Benchmarking
    15.3. Market Share Analysis of Top Players
        15.3.1. By Regional
        15.3.2. By Diagnosis Procedure
        15.3.3. By Drug Type
        15.3.4. By Medication Class
16. Competition Analysis
    16.1. Competition Deep Dive
        16.1.1. Nielsen BioSciences
            16.1.1.1. Overview
            16.1.1.2. Product Portfolio
            16.1.1.3. Profitability by Market Segments
            16.1.1.4. Sales Footprint
            16.1.1.5. Strategy Overview
                16.1.1.5.1. Marketing Strategy
        16.1.2. Verrica Pharmaceutical
            16.1.2.1. Overview
            16.1.2.2. Product Portfolio
            16.1.2.3. Profitability by Market Segments
            16.1.2.4. Sales Footprint
            16.1.2.5. Strategy Overview
                16.1.2.5.1. Marketing Strategy
        16.1.3. Aclaris Therapeutics, Inc.
            16.1.3.1. Overview
            16.1.3.2. Product Portfolio
            16.1.3.3. Profitability by Market Segments
            16.1.3.4. Sales Footprint
            16.1.3.5. Strategy Overview
                16.1.3.5.1. Marketing Strategy
        16.1.4. KinoPharma, Inc.
            16.1.4.1. Overview
            16.1.4.2. Product Portfolio
            16.1.4.3. Profitability by Market Segments
            16.1.4.4. Sales Footprint
            16.1.4.5. Strategy Overview
                16.1.4.5.1. Marketing Strategy
        16.1.5. pHion Therapeutics
            16.1.5.1. Overview
            16.1.5.2. Product Portfolio
            16.1.5.3. Profitability by Market Segments
            16.1.5.4. Sales Footprint
            16.1.5.5. Strategy Overview
                16.1.5.5.1. Marketing Strategy
        16.1.6. Orgenesis
            16.1.6.1. Overview
            16.1.6.2. Product Portfolio
            16.1.6.3. Profitability by Market Segments
            16.1.6.4. Sales Footprint
            16.1.6.5. Strategy Overview
                16.1.6.5.1. Marketing Strategy
        16.1.7. Novan
            16.1.7.1. Overview
            16.1.7.2. Product Portfolio
            16.1.7.3. Profitability by Market Segments
            16.1.7.4. Sales Footprint
            16.1.7.5. Strategy Overview
                16.1.7.5.1. Marketing Strategy
        16.1.8. Cassopeia Pharmaceuticals
            16.1.8.1. Overview
            16.1.8.2. Product Portfolio
            16.1.8.3. Profitability by Market Segments
            16.1.8.4. Sales Footprint
            16.1.8.5. Strategy Overview
                16.1.8.5.1. Marketing Strategy
        16.1.9. Innovax
            16.1.9.1. Overview
            16.1.9.2. Product Portfolio
            16.1.9.3. Profitability by Market Segments
            16.1.9.4. Sales Footprint
            16.1.9.5. Strategy Overview
                16.1.9.5.1. Marketing Strategy
        16.1.10. Torii Pharmaceutical Co. Ltd.
            16.1.10.1. Overview
            16.1.10.2. Product Portfolio
            16.1.10.3. Profitability by Market Segments
            16.1.10.4. Sales Footprint
            16.1.10.5. Strategy Overview
                16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Recommendations

Healthcare

Skin Grafting System Market

December 2022

REP-GB-1762

250 pages

Healthcare

Scabies Treatment Market

November 2022

REP-GB-1411

250 pages

Healthcare

Skin Replacement Market

June 2022

REP-GB-588

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Common Warts Market

Schedule a Call